ICU Medical, Inc.
ICUI Healthcare Medical Instruments & Supplies
ICU Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, down 6.33% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 46.9%, free cash flow grew 656.0% and total debt fell 7.96%, each against the same quarter a year earlier.
Follow ICUI
ICU Medical, Inc. (ICUI) EV/Sales
As of 16 October 2026, ICU Medical, Inc. (ICUI) trades at a EV/Sales of 2.3×. Over the past ten years it has ranged from 1.5× (November 2023) to 5.8× (June 2017); the current reading is higher than 26% of that period. That is below the Medical Instruments & Supplies industry median of 2.9× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.0× | (5.19%) |
| FY2024 | 2.1× | 25.55% |
| FY2023 | 1.7× | (26.61%) |
| FY2022 | 2.3× | (32.76%) |
| FY2021 | 3.4× | 5.60% |
| FY2020 | 3.2× | 14.06% |
| FY2019 | 2.8× | (8.95%) |
| FY2018 | 3.1× | 0.67% |
| FY2017 | 3.1× | (39.12%) |
| FY2016 | 5.1× | 23.59% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.1× | 9.58% |
| Mar 2026 | 1.9× | (3.50%) |
| Dec 2025 | 2.0× | 16.11% |
| Sep 2025 | 1.7× | (5.27%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NVST Envista Holdings Corporation compare | 1.4× |
| BLCO Bausch + Lomb Corporation compare | 2.0× |
| ICUI ICU Medical, Inc. | 2.3× |
| WRBY Warby Parker Inc. compare | 2.9× |
| MMSI Merit Medical Systems, Inc. compare | 3.6× |
| TFX Teleflex Incorporated compare | 3.6× |
| STVN Stevanato Group S.p.A. compare | 3.9× |
| ATRC AtriCure, Inc. compare | 4.7× |
| PLSE Pulse Biosciences, Inc compare | 2,555× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)